N = 408 T2D patients undergoing PCI divided into three groups: 136 treated with new-antidiabetic drugs, 136 treated with standard-antidiabetic therapy, and 136 patients without diabetes. Mean follow-up was not reported. Exclusion criteria: not reported. The patients treated with SGLT2Is presented pre-PCI mean creatinine levels significantly lower (0.83 ± 0.16 mg/dL) than those treated with DPP-4 inhibitors (1.04 ± 0.34 mg/dL) and GLP-1 analogues (1.05 ± 0.39 mg/dL), (p for trend = 0.009). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.